Rationale And Objectives: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0). This system showed promising results in single-center studies. We aim to evaluate the prognostic performance of RECIP 1.0 in assessing treatment outcomes in metastatic prostate cancer patients with a systematic review and meta-analysis.
Materials And Methods: Searches were conducted across PubMed/MEDLINE, EMBASE, and Web of Science databases through March 2024. Only studies involving patients with metastatic prostate cancer who underwent PSMA PET/CT to assess therapeutic response and who were evaluated using the RECIP 1.0 criteria were included. Pooled hazard ratios for mortality and concordance indices (c-index) of RECIP were assessed. A secondary analysis compared RECIP 1.0 to PSMA PET Progression Criteria (PPP) in head-to-head studies.
Results: From an initial 553 reports, eight met the eligibility criteria after full-text review (n=516 patients) and six underwent quantitative analysis. RECIP 1.0 significantly differentiated between disease progression and non-progression in terms of mortality risk (HR: 3.48; 95% CI: 2.64-4.59). A sub-analysis of three studies with 174 patients demonstrated a pooled c-index of 0.68 (95% CI: 0.65-0.71). Comparison involving 224 patients from three studies indicated a non-significant trend favoring RECIP 1.0 over PPP.
Conclusion: RECIP 1.0 offers robust prognostic value for assessing metastatic prostate cancer treatment outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acra.2024.12.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of tribbles homolog 2 in cell proliferation.
Cell Commun Signal
January 2025
School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Tribbles homolog 2 (TRIB2), a pseudoserine/threonine kinase, is a member of the TRIB family. TRIB2 primarily regulates cell proliferation through its scaffold or adaptor effect on promoting the degradation of target proteins by E3 ligase-dependent ubiquitination and regulating mitogen-activated protein kinase (MAPK) and protein kinase B (AKT) signaling pathways. TRIB2 is not only involved in the physiological proliferation of cells (granulosa cells, myoblasts, naive T cells, and thymocytes) during normal development but also in the pathological proliferation of vascular smooth muscle cells and a variety of cancer cells (lung cancer cells, liver cancer cells, leukemia cells, pancreatic cancer cells, gastric cancer cells, prostate cancer cells, thyroid cancer cells, cervical cancer cells, melanoma cells, colorectal cancer cells, ovarian cancer cells and osteosarcoma cells) under disease conditions.
View Article and Find Full Text PDFRelationship between albumin-globulin ratio and prostate-specific antigen: a cross-sectional study based on NHANES 2003-2010.
BMC Urol
January 2025
The Central Hospital of Yongzhou, Yongzhou, Hu Nan, 425000, China.
Purpose: The albumin-globulin ratio (AGR) influences the development of prostate cancer; however, the relationship between AGR and prostate-specific antigen (PSA) has not been reported.
Methods: This cross-sectional investigation used comprehensive AGR versus PSA data from men with 40 years of age and older, who participated in the National Health and Nutrition Examination Survey (NHANES) from 2003 to 2010, spanning 4 investigation cycles, as only these cycles contained complete PSA data. To evaluate the nonlinear relationship between the ARG and PSA level, a regression utilizing smoothed curve fitting (penalized spline approach) and a generalized additive model (GAM) were employed.
Prostate MRI and clinicopathologic risk calculator to predict laterality of extraprostatic extension at radical prostatectomy.
Prostate Cancer Prostatic Dis
January 2025
Northwestern University, Feinberg School of Medicine, Department of Urology, Chicago, IL, 60611, USA.
Background: Traditional nomograms can inform the presence of extraprostatic extension (EPE) but not laterality, which remains important for surgical planning, and have not fully incorporated multiparametric MRI data. We evaluated predictors of side-specific EPE on surgical pathology including MRI characteristics and developed side-specific EPE risk calculators.
Methods: This was a retrospective cohort of patients evaluated with mpMRI prior to radical prostatectomy (RP) in our eleven hospital healthcare system from July 2018-November 2022.
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer.
Prostate Cancer Prostatic Dis
January 2025
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany.
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has a high negative predictive value (NPV) in determining lymph node invasion (LNI) in men with intermediate-risk disease undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND). We hypothesized that PSMA PET may be used to reduce the number of unnecessary PLND procedures performed.
Objective: To assess BCR-free survival of intermediate risk prostate cancer patients with a negative PSMA PET who underwent PLND vs.
Analysis of the predictive value of the prostate-specific antigen-to-neutrophil ratio for the diagnosis of prostate cancer.
Discov Oncol
January 2025
Department of Urology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, 750004, Ningxia, China.
Background: Currently, serum PSA is the most commonly used screening tool in clinical practice. However, PSA levels in the range of 4-10 ng/ml are considered the 'grey zone' of prostate cancer screening. Patients within this range need to be further evaluated using additional parameters such as PSA ratio, PSA density, and other indices to determine the necessity of prostate biopsy (PBx).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!